Holen Sie sich die Stockscreener-App
2.15
8.59%
0.17
Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten
Dogwood Therapeutics, Inc. 2026: Revenue ($14.06M), EPS ($0.34) — 10-Q Summary - TradingView
Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook - Stock Titan
Armistice Capital (DWTX) discloses 9.99% Dogwood Therapeutics ownership in 13G/A - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS - marketbeat.com
Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Dogwood Therapeutics Reports $11.5 Million Second-Quarter Net Loss - Quiver Quantitative
Dogwood Therapeutics reports Q2 2026 net loss of $11.5M, IPR&D charge of $9.19M; $9.6M cash - TradingView
DWTX: Halneuron Phase 2b trial nears completion as Q2 net loss widens on higher R&D and impairment - TradingView
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Pain drug trial enrolls 217 as Dogwood expects fall 2026 results - Stock Titan
Dogwood Therapeutics Inc (DWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dogwood Therapeutics Inc (DWTX) Stock News Today - TradingKey
Dogwood Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Wednesday - marketbeat.com
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3%What's Next? - marketbeat.com
Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline - Bitget
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise - dars.gov.et
Dogwood Therapeutics, Inc. Revenue Breakdown – NASDAQ:DWTX - TradingView
Dogwood Therapeutics Inc (DWTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dogwood Therapeutics Inc (DWTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DWTX|Dogwood Therapeutics Inc|Price:1.530|Chg%:+0.030 - TradingKey
Dogwood Therapeutics Market Sentiment - Benzinga España
Dogwood Therapeutics Inc (DWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dogwood Therapeutics Inc (DWTX) Balance Sheet - TradingKey
Dogwood Therapeutics Inc (DWTX) Income Statement - TradingKey
Dogwood Therapeutics Inc (DWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower Net Loss Exceeds Consensus Expectations Amid Clinical DevelopmentFinal Results - dars.gov.et
TradingKey - TradingKey
Dogwood Therapeutics Inc (DWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dogwood Therapeutics Inc (DWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial - marketscreener.com
Dogwood (DWTX) Reaches Enrollment Milestone in HAL-CINP Phase 2b Trial - GuruFocus
Dogwood Therapeutics enrolls 200 patients in pain treatment trial - Investing.com
Dogwood Reports 4.5% Early Termination Rate Among First 200 Patients - Stock Titan
Enterprise value to revenue forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Dogwood Therapeutics (DWTX) Slips 1% as Shares Test Support Near $1.36Ratio Spread Trade - dars.gov.et
Dogwood Therapeutics (DWTX) Slips Modestly, Holds Above Key Support LevelBull Flag - dars.gov.et
Dogwood Therapeutics (DWTX) Edges Higher Amid Tight Trading RangeRSI Overbought Alerts - dars.gov.et
Dogwood Therapeutics (DWTX) Holds Steady at $1.42 – Key Levels in FocusBuffered ETF - dars.gov.et
Virios Therapeutics weighs strategic options as development focus remains on fibromyalgia - Ad-hoc-news.de
Dogwood Therapeutics (DWTX) Rises 4.35% as Stock Climbs Toward Resistance LevelThrowback Trade - dars.gov.et
Price to sales forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Enterprise value to EBIT forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Price to earnings forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
DWTXDogwood Therapeutics Inc Latest SEC Filings - Finviz
Dogwood Therapeutics Names OrbiMed’s Iain Dukes Chair of Scientific Advisory Board - citybiz
Dogwood Therapeutics appoints Iain Dukes to lead advisory board - Investing.com
Dogwood Therapeutics appoints Iain Dukes to lead advisory board By Investing.com - Investing.com Nigeria
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board - GlobeNewswire
Dogwood Therapeutics, Inc.(NasdaqCM:DWTX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Dogwood Therapeutics, Inc.(NasdaqCM: DWTX) added to Russell Microcap Index - marketscreener.com
Dogwood Therapeutics, Inc.(NasdaqCM: DWTX) added to Russell 3000E Index - marketscreener.com
DWTX Forecast — Price Target — Prediction for 2027 - TradingView
Dogwood Therapeutics Inc Actuals & Estimates (NASDAQ:DWTX) - TradingView
Number of shareholders of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: EPS Beat Driven by Cost Discipline Despite No Revenue - po-news-eg.net
Dogwood Therapeutics (DWTX) Bounces 4% Off Support as Bulls Test Key Resistance LevelTotal Put Call - dars.gov.et
Dogwood Therapeutics Shareholders Approve Key Governance Measures - The Globe and Mail
Dogwood Therapeutics shareholders approve board proposals at annual meeting By Investing.com - Investing.com South Africa
Dogwood Therapeutics, Inc. Announces Amendments to Articles of Incorporation and Key Shareholder Voting Results – June 2026 – Minichart - Minichart
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):